Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Expert Q&A
Expert Q&A
11/04/2025
Daniel Lenihan, MD, FACC, FESC
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
11/04/2025
Expert Q&A
Expert Q&A
11/04/2025
Daniel Lenihan, MD, FACC, FESC
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
11/04/2025
Expert Q&A
Expert Q&A
11/04/2025
Daniel Lenihan, MD, FACC, FESC
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
11/04/2025